Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VBI-2902,Aluminum Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VBI-2902 is a monovalent Covid-19-specific vaccine expressing the SARS-CoV-2 spike protein. The adaptive Phase 1/2 clinical study will evaluate the safety, tolerability, and immunogenicity of VBI-2902, adjuvanted with aluminum phosphate.
Brand Name : VBI-2902
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 09, 2021
Lead Product(s) : VBI-2902,Aluminum Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?